Latest News and Press Releases

BOSTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its fourth quarter and full year 2021 financial results on Thursday, February 24,...

Completion of three pivotal trials in 2021 enables restructuring of the operating infrastructureNon-Sales headcount reduced by approximately 20%Reductions focused on areas that supported abaloparatide...

FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021The boxed warning had referred to the potential risk of osteosarcomaAction follows review of long-term...

Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine...

BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET...

The wearABLe study did not demonstrate non-inferiority of abalo-TDS to TYMLOS®Lumbar spine BMD at 12 months vs. baseline for abalo-TDS was +7.1% vs. TYMLOS +10.9%Both abalo-TDS and TYMLOS 12-month...

BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that management will participate in the Stifel 2021 Virtual Healthcare...

TYMLOS® Q3, 2021 net revenue: $57 million, +13% vs. Q3, 2020Added 4,461 new patients on TYMLOS in Q3, 2021, +10% vs. Q3, 2020Adjusted EBITDA of ($11) million vs. $9 million in Q3, 2020 which included...

BOSTON, Oct. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday, Oct. 20, by Radius Health, Inc. (NASDAQ: RDUS), please note that the dial-in numbers were listed...

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021. The Company will...